Table 2.
Average annual percentage changes in incidence by HER2/HR status among women aged 20–49 years diagnosed with stage I-III breast cancer, 2010–2016, SEER 18 registries
| 20–29 Years | 30–39 Years | 40–49 Years | |
|---|---|---|---|
| AAPC (95% CI) | AAPC (95% CI) | AAPC (95% CI) | |
| Analytic sample | |||
| HER2+/HR+ | 3.58 (−1.56, 9.00) | 4.43 (2.75, 6.14) | 3.70 (1.26, 6.20) |
| HER2+/HR− | 5.80 (−3.45, 15.95) | 3.04 (0.49, 5.66) | 2.63 (−0.54, 5.90) |
| HER2−/HR+ | 0.49 (−4.43, 5.65) | 1.20 (−1.21, 3.67) | 1.43 (0.32, 2.55) |
| HER2−/HR− | 3.64 (−1.82, 9.40) | 0.44 (−0.97, 1.87) | −1.73 (−4.28, 0.89) |
| Stage I | |||
| HER2+/HR+ | −0.90 (−18.11, 19.91) | 3.68 (0.28, 7.21) | 2.37 (−1.33, 6.21) |
| HER2+/HR− | −2.68 (−28.89, 33.18) | 1.91 (−7.37, 12.10) | −0.34 (−5.48, 5.08) |
| HER2−/HR+ | −1.77 (−8.63, 5.61) | 1.35 (−1.34, 4.10) | 2.02 (0.48, 3.59) |
| HER2−/HR− | −4.34 (−11.76, 3.70) | −1.63 (−5.67, 2.58) | −2.13 (−5.35, 1.20) |
| Stage II | |||
| HER2+/HR+ | 4.33 (−0.79, 9.72) | 6.04 (2.65, 9.55) | 5.52 (1.60, 9.59) |
| HER2+/HR− | 13.51 (−1.07, 30.24) | 6.68 (0.66, 13.06) | 7.82 (3.15, 12.70) |
| HER2−/HR+ | 1.22 (−5.71, 8.66) | 2.04 (−0.53, 4.67) | 1.56 (0.48, 2.65) |
| HER2−/HR− | 5.31 (−5.28, 17.08) | 0.67 (−2.20, 3.62) | −0.67 (−3.17, 1.91) |
| Stage III | |||
| HER2+/HR+ | 3.53 (−5.36, 13.26) | 1.36 (−4.49, 7.58) | 2.05 (−3.14, 7.52) |
| HER2+/HR− | 2.28 (−14.96, 23.02) | −1.92 (−6.00, 2.33) | −2.42 (−5.35, 0.61) |
| HER2−/HR+ | 2.12 (−3.90, 8.52) | −1.00 (−4.54, 2.67) | −1.10 (−2.56, 0.37) |
| HER2−/HR− | 3.09 (−11.86, 20.57) | 1.99 (−0.78, 4.84) | −4.07 (−6.94, −1.12) |
| Non-Hispanic white | |||
| HER2+/HR+ | 6.13 (−1.99, 14.92) | 3.77 (0.87, 6.76) | 3.09 (−0.81, 7.15) |
| HER2+/HR− | 10.48 (−1.28, 23.64) | 3.60 (1.83, 5.40) | 2.78 (−2.58, 8.43) |
| HER2−/HR+ | 0.99 (−3.92, 6.15) | 0.76 (−1.98, 3.58) | 1.39 (0.17, 2.64) |
| HER2−/HR− | 5.34 (−3.25, 14.69) | 0.49 (−2.96, 4.06) | −2.07 (−4.03, −0.08) |
| Non-Hispanic black | |||
| HER2+/HR+ | −7.27 (−19.76, 7.17) | 2.41 (−2.01, 7.04) | 2.42 (−1.21, 6.19) |
| HER2+/HR− | −8.19 (−24.68, 11.92) | 1.64 (−2.95, 6.44) | 4.71 (−0.53, 10.24) |
| HER2−/HR+ | −5.83 (−15.65, 5.14) | 2.48 (−2.41, 7.63) | 0.57 (−1.30, 2.47) |
| HER2−/HR− | −2.04 (−10.20, 6.87) | 0.25 (−5.07, 5.87) | −0.70 (−5.35, 4.19) |
| Non-Hispanic Asian or Pacific Islander | |||
| HER2+/HR+ | 7.81 (−8.52, 27.05) | 3.09 (1.45, 4.76) | 3.13 (−2.77, 9.40) |
| HER2+/HR− | −4.81 (−22.48, 16.87) | 2.48 (−8.86, 15.25) | 1.24 (−3.58, 6.30) |
| HER2−/HR+ | 1.64 (−10.29, 15.16) | 0.20 (−3.49, 4.02) | 2.85 (0.20, 5.57) |
| HER2−/HR− | −5.25 (−28.29, 25.19) | −2.06 (−7.11, 3.28) | −2.23 (−10.23, 6.49) |
| Hispanic (all races)a | |||
| HER2+/HR+ | 3.58 (−7.16, 15.56) | 9.42 (5.11, 13.91) | 7.46 (4.48, 10.53) |
| HER2+/HR− | 2.67 (−22.83, 36.60)b | 1.86 (−5.43, 9.72) | 0.30 (−5.93, 6.93) |
| HER2−/HR+ | 1.63 (−4.25, 7.88) | 2.42 (−0.56, 5.49) | 2.48 (−0.78, 5.85) |
| HER2−/HR− | 6.55 (3.32, 9.88) | 1.24 (−1.70, 4.27) | −1.16 (−7.26, 5.35) |
Abbreviations: AAPC, average annual percent change; CI, confidence interval; HER2, human epidermal growth factor receptor-2; HR, hormone receptor; SEER, Surveillance, Epidemiology, and End Results.
Women identified by the Alaska Native Registry were excluded from incidence estimations for the Hispanic group, as this registry only collects cases from the Native American and Alaska Native populations within the state.
No cases were observed in 2012 for this group. A case count of 0.25 was used for 2012 in order to estimate the AAPC.
Results for non-Hispanic American Indian/Alaska Native women were not presented due to sparse case counts for these strata.